Zydus Lifesciences gets USFDA nod for acne treatment gel
The final approval by the US Food and Drug Administration (USFDA) is for Dapsone gel of strength 7.5 per cent, Zydus Lifesciences said in a regulatory filing.
)
Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to market its generic version of Dapsone gel used to treat acne.
The final approval by the US Food and Drug Administration (USFDA) is for Dapsone gel of strength 7.5 per cent, Zydus Lifesciences said in a regulatory filing.
Dapsone gel is used to treat acne and will be manufactured at the group's topical manufacturing facility in Changodar, Ahmedabad, it added.
Dapsone gel, 7.5 per cent had annual sales of USD 35.8 million in the US, Zydus Lifesciences said citing IQVIA MAT March 2024 data.
Catch all the updates of the May 9 session on Dalal Street here. For all other news related to business, politics, tech and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
01:12 PM IST
Zydus Lifesciences gets USFDA nod to produce prostrate cancer drug 
Zydus gets USFDA nod to produce generic prostate cancer drug